Blocking Monocytic Myeloid-Derived Suppressor Cell Function via Anti-DC-HIL/GPNMB Antibody Restores the

Animals Antineoplastic Agents, Immunological / pharmacology Cell Line, Tumor Disease Progression Humans Immunophenotyping Interferon-gamma Lymphocytes, Tumor-Infiltrating / drug effects Membrane Glycoproteins / antagonists & inhibitors Mice Myeloid-Derived Suppressor Cells / drug effects Neoplasms / drug therapy T-Lymphocytes / drug effects Tumor Microenvironment / genetics

Journal

Clinical cancer research : an official journal of the American Association for Cancer Research
ISSN: 1557-3265
Titre abrégé: Clin Cancer Res
Pays: United States
ID NLM: 9502500

Informations de publication

Date de publication:
15 01 2019
Historique:
received: 26 01 2018
revised: 15 05 2018
accepted: 12 07 2018
pubmed: 28 7 2018
medline: 28 2 2020
entrez: 28 7 2018
Statut: ppublish

Résumé

Blocking the function of myeloid-derived suppressor cells (MDSC) is an attractive approach for cancer immunotherapy. Having shown DC-HIL/GPNMB to be the T-cell-inhibitory receptor mediating the suppressor function of MDSCs, we evaluated the potential of anti-DC-HIL mAb as an MDSC-targeting cancer treatment. Patients with metastatic cancer ( Patients with metastatic cancer had high blood levels of DC-HIL Blocking DC-HIL function is a potentially useful treatment for at least colorectal cancer with high blood levels of DC-HIL

Identifiants

DOI: 10.1158/1078-0432.CCR-18-0330 PMID: 30049749 PMC: PMC7315386
pubmed: 30049749
pii: 1078-0432.CCR-18-0330
doi: 10.1158/1078-0432.CCR-18-0330
pmc: PMC7315386
mid: NIHMS1595628
doi:

Substances chimiques

Antineoplastic Agents, Immunological 0
GPNMB protein, human 0
Membrane Glycoproteins 0
Interferon-gamma 82115-62-6

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, U.S. Gov't, Non-P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

828-838

Subventions

Organisme : BLRD VA
ID : I01 BX004069
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA142543
Pays : United States
Organisme : NCI NIH HHS
ID : P50 CA196516
Pays : United States

Commentaires et corrections

Type : CommentIn

Informations de copyright

©2018 American Association for Cancer Research.

Références

PLoS One. 2013;8(2):e57114
pubmed: 23437326
Clin Cancer Res. 2016 Aug 1;22(15):3924-36
pubmed: 26957562
Exp Cell Res. 2014 Apr 15;323(1):100-11
pubmed: 24589892
J Biol Chem. 2001 Mar 16;276(11):8125-34
pubmed: 11114299
J Invest Dermatol. 2016 Sep;136(9):1801-1810
pubmed: 27236103
J Immunol. 2008 Oct 15;181(8):5791-802
pubmed: 18832739
Methods. 2003 Oct;31(2):143-9
pubmed: 12957572
Oncoimmunology. 2015 Jan 22;4(3):e995541
pubmed: 25949922
Mol Cancer Ther. 2015 Apr;14(4):847-56
pubmed: 25695955
Cancer Immunol Immunother. 2012 Sep;61(9):1373-85
pubmed: 22215137
Sci Rep. 2015 Mar 09;5:8913
pubmed: 25746680
Nat Commun. 2016 Jul 06;7:12150
pubmed: 27381735
J Thorac Oncol. 2016 Jul;11(7):976-88
pubmed: 26944305
J Clin Oncol. 2014 Nov 10;32(32):3619-25
pubmed: 25267761
Cancer Res. 2010 Jul 15;70(14):5778-87
pubmed: 20570888
Int J Cancer. 2004 May 20;110(1):51-60
pubmed: 15054868
J Invest Dermatol. 2014 Nov;134(11):2839-2842
pubmed: 24933321
J Immunol. 2014 Mar 15;192(6):2576-84
pubmed: 24516197
Adv Cancer Res. 2015;128:95-139
pubmed: 26216631
Cancer Res. 2004 Feb 1;64(3):1140-5
pubmed: 14871849
J Immunol. 2007 Nov 1;179(9):5778-84
pubmed: 17947650
Oncogene. 2015 Oct;34(43):5494-504
pubmed: 25772243
Cell Commun Signal. 2015 Mar 24;13:19
pubmed: 25889792
J Leukoc Biol. 2017 Aug;102(2):381-391
pubmed: 28179538
J Clin Oncol. 2014 Nov 10;32(32):3659-66
pubmed: 25267741
Cancer Immunol Res. 2014 Aug;2(8):812-21
pubmed: 24844912
Ann N Y Acad Sci. 2014 Jun;1319:47-65
pubmed: 24965257
Cancer Immunol Immunother. 2009 May;58(5):687-97
pubmed: 18828017
Cancer Immunol Immunother. 2012 Feb;61(2):193-202
pubmed: 21874302
Nature. 2017 Mar 30;543(7647):728-732
pubmed: 28321130
Eur J Immunol. 2009 Apr;39(4):965-74
pubmed: 19350579
J Invest Dermatol. 2014 Nov;134(11):2784-2794
pubmed: 24936834
Steroids. 2018 May;133:102-107
pubmed: 29097143
J Clin Invest. 2006 Oct;116(10):2587-90
pubmed: 17016554
Cancer Immunol Immunother. 2017 Nov;66(11):1437-1447
pubmed: 28688082
Clin Cancer Res. 2010 Apr 1;16(7):2147-56
pubmed: 20215530
J Clin Oncol. 2015 May 10;33(14):1609-19
pubmed: 25847941
J Immunol. 2009 Oct 15;183(8):5190-8
pubmed: 19794069
Blood. 2007 May 15;109(10):4320-7
pubmed: 17284525
Clin Cancer Res. 2006 Apr 1;12(7 Pt 1):1970-82
pubmed: 16609006
Clin Chem. 2001 Apr;47(4):624-30
pubmed: 11274010
Mol Cancer Res. 2007 Oct;5(10):1001-14
pubmed: 17951401
BioDrugs. 2014 Jun;28(3):253-63
pubmed: 24496926
Expert Opin Biol Ther. 2012 Feb;12(2):259-63
pubmed: 22229970
J Exp Med. 2009 Dec 21;206(13):3015-29
pubmed: 20008522
Cancer Treat Rev. 2017 Jan;52:71-81
pubmed: 27951441
Curr Drug Saf. 2016;11(1):62-8
pubmed: 26412670
Clin Cancer Res. 2015 Aug 15;21(16):3771-82
pubmed: 25967142
Clin Cancer Res. 2006 Feb 15;12(4):1373-82
pubmed: 16489096
J Exp Med. 2017 Apr 3;214(4):895-904
pubmed: 28302645

Auteurs

Masato Kobayashi (M)

Department of Dermatology, The University of Texas Southwestern Medical Center, Dallas, Texas.

Jin-Sung Chung (JS)

Department of Dermatology, The University of Texas Southwestern Medical Center, Dallas, Texas.

Muhammad Beg (M)

Department of Internal Medicine, The University of Texas Southwestern Medical Center, Dallas, Texas.

Yull Arriaga (Y)

Department of Internal Medicine, The University of Texas Southwestern Medical Center, Dallas, Texas.

Udit Verma (U)

Department of Internal Medicine, The University of Texas Southwestern Medical Center, Dallas, Texas.

Kevin Courtney (K)

Department of Internal Medicine, The University of Texas Southwestern Medical Center, Dallas, Texas.

John Mansour (J)

Department of Surgery, The University of Texas Southwestern Medical Center, Dallas, Texas.

Barbara Haley (B)

Department of Internal Medicine, The University of Texas Southwestern Medical Center, Dallas, Texas.

Saad Khan (S)

Department of Internal Medicine, The University of Texas Southwestern Medical Center, Dallas, Texas.

Yutaka Horiuchi (Y)

Department of Microbiology, Faculty of Medicine, Saitama Medical University, Iruma District, Saitama Prefecture, Japan.

Vijay Ramani (V)

Department of Dermatology, The University of Texas Southwestern Medical Center, Dallas, Texas.

David Harker (D)

Department of Dermatology, The University of Texas Southwestern Medical Center, Dallas, Texas.

Purva Gopal (P)

Department of Pathology, The University of Texas Southwestern Medical Center, Dallas, Texas.

Farshid Araghizadeh (F)

Department of Surgery, The University of Texas Southwestern Medical Center, Dallas, Texas.

Ponciano D Cruz (PD)

Department of Dermatology, The University of Texas Southwestern Medical Center, Dallas, Texas.

Kiyoshi Ariizumi (K)

Department of Dermatology, The University of Texas Southwestern Medical Center, Dallas, Texas. kiyoshi.ariizumi@utsouthwestern.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Blocking Monocytic Myeloid-Derived Suppressor...
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Antinéoplasiques › Antinéoplasiques immunologiques › Blocking Monocytic Myeloid-Derived Suppressor...
questionsmedicales.fr › Cellules › Cellules cultivées › Cellules cancéreuses en culture › Lignée cellulaire tumorale › Blocking Monocytic Myeloid-Derived Suppressor...
questionsmedicales.fr › États, signes et symptômes pathologiques › Processus pathologiques › Caractéristiques de la maladie › Évolution de la maladie › Blocking Monocytic Myeloid-Derived Suppressor...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Blocking Monocytic Myeloid-Derived Suppressor...
questionsmedicales.fr › Techniques d'investigation › Techniques immunologiques › Tests immunologiques › Immunophénotypage › Blocking Monocytic Myeloid-Derived Suppressor...
questionsmedicales.fr › Facteurs biologiques › Protéines et peptides de signalisation intercellulaire › Cytokines › Lymphokines › Facteurs d'activation des macrophages › Interféron gamma › Blocking Monocytic Myeloid-Derived Suppressor...
questionsmedicales.fr › Systèmes sanguin et immunitaire › Système immunitaire › Leucocytes › Agranulocytes › Lymphocytes › Lymphocytes TIL › Blocking Monocytic Myeloid-Derived Suppressor...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines membranaires › Glycoprotéines membranaires › Blocking Monocytic Myeloid-Derived Suppressor...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Rodentia › Muridae › Murinae › Souris › Blocking Monocytic Myeloid-Derived Suppressor...
questionsmedicales.fr › Cellules › Cellules myéloïdes › Cellules myéloïdes suppressives › Blocking Monocytic Myeloid-Derived Suppressor...
questionsmedicales.fr › Tumeurs › Blocking Monocytic Myeloid-Derived Suppressor...
questionsmedicales.fr › Systèmes sanguin et immunitaire › Système immunitaire › Leucocytes › Agranulocytes › Lymphocytes › Lymphocytes T › Blocking Monocytic Myeloid-Derived Suppressor...
questionsmedicales.fr › Phénomènes physiologiques cellulaires › Microenvironnement cellulaire › Microenvironnement tumoral › Blocking Monocytic Myeloid-Derived Suppressor...